Business Context and Reporting Period
Company: Abbott Laboratories
Filing Type: Form 8-K (Current Report)
Date of Report: October 16, 2013
Event: Announcement of third-quarter 2013 results of operations.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The report serves as a notification that results were announced and directs readers to a press release (Exhibit 99.1) for detailed figures.
The filing highlights the use of non-GAAP financial measures, specifically "net earnings excluding specified items," to adjust for:
- Cost reduction initiatives and philanthropic contributions.
- Costs related to the separation of the research-based pharmaceuticals business (AbbVie Inc.).
- Interest expense adjustments reflecting the post-separation capital structure.
- Tax expense adjustments for prior year resolutions and litigation reserves.
- Separation-related and integration costs.
- Intangible amortization expense.
Material Changes
The filing does not explicitly state material changes in financial metrics compared to the prior period. It notes that the company is in the process of separating its research-based pharmaceuticals business into AbbVie Inc., which impacts the presentation of financial results through specific adjustments.
Guidance, Outlook, and Risks
Management Commentary: Management utilizes non-GAAP measures internally to monitor performance and believes they provide investors with greater visibility into ongoing business operations by excluding unusual or unpredictable costs associated with the AbbVie separation.
Cautionary Note: The company cautions investors that non-GAAP measures should be considered in addition to, and not as a substitute for, GAAP financial measures.
Risks/Contingencies: The filing references costs related to litigation reserves and the structural separation of AbbVie Inc. as factors influencing financial reporting.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated October 16, 2013) for specific Q3 2013 revenue and earnings figures.
- Verify the reconciliation between GAAP and non-GAAP net earnings to understand the impact of AbbVie separation costs.
- Assess the magnitude of intangible amortization and litigation reserves excluded from non-GAAP results.
- Confirm the timeline and financial implications of the ongoing separation of AbbVie Inc.